{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:50Z","timestamp":1792788350087,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["24FE2002; 25FE2001"],"award-info":[{"award-number":["24FE2002; 25FE2001"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004298","name":"Secom Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016241","name":"Nakayama Foundation for Human Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016241","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSA WAO 2020 Memorial Research Grant Program"},{"name":"Japanese Society of Allergology, Clinical Research Support Program","id":[{"id":"https:\/\/ror.org\/0263b6f89","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ek0410130"],"award-info":[{"award-number":["JP25ek0410130"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rituximab can cause immediate and delayed immune reactions, including rituximab-induced serum sickness (RISS). However, the temporal and mechanistic relationship between these reactions is unclear. We report a case in which RISS developed several days after rituximab-induced anaphylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 70-year-old woman with stage I mucosa-associated lymphoid tissue lymphoma was initially treated with weekly rituximab monotherapy. Four days after the third infusion, she developed fever, nonpruritic erythema, and arthralgia, which resolved spontaneously. When rituximab was re-administered, she immediately developed symptoms consistent with anaphylaxis, prompting treatment discontinuation. One year later, rituximab was re-started due to slight disease progression. The infusion induced nasal congestion and hoarseness but was completed under hydrocortisone. Eight days later, she presented with fever, widespread pruritic plaques, vomiting, diarrhea, and hypotension. Laboratory testing revealed elevated inflammatory markers without evidence of bacterial infection. Human anti-chimeric antibody levels were markedly elevated (&gt;\u20095000 ng\/mL). Intradermal testing with rituximab induced both an immediate wheal and a delayed erythematous flare lasting several days, indicating coexisting immediate-type hypersensitivity and RISS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that RISS may occur several days after the resolution of rituximab-induced anaphylaxis. When immediate reactions occur after rituximab administration, patient education to ensure prompt reporting of delayed reactions is essential. Skin testing supported the identification of sequential immediate and delayed rituximab hypersensitivity in this case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-026-01050-0","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T12:43:17Z","timestamp":1783255397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Shiori","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utako","family":"Okata-Karigane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umi","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Fukushima-Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"1050_CR1","doi-asserted-by":"publisher","first-page":"107565","DOI":"10.1016\/j.intimp.2021.107565","volume":"95","author":"Z Zian","year":"2021","unstructured":"Zian Z, Berry SPD, Bahmaie N, Ghotbi D, Kashif A, Madkaikar M, et al. The clinical efficacy of rituximab administration in autoimmunity disorders, primary immunodeficiency diseases, and malignancies. Int Immunopharmacol. 2021;95:107565.","journal-title":"Int Immunopharmacol"},{"key":"1050_CR2","doi-asserted-by":"publisher","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","volume":"11","author":"GE Fouda","year":"2020","unstructured":"Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020;11:572863.","journal-title":"Front Pharmacol"},{"key":"1050_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45:334\u201340.","journal-title":"Semin Arthritis Rheum"},{"key":"1050_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases than in hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59\u201364.","journal-title":"Eur J Intern Med"},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","volume":"130","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Payne AS. Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient. J Allergy Clin Immunol. 2012;130:800\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"1050_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/all.15032","volume":"77","author":"A Muraro","year":"2022","unstructured":"Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022;77:357\u201377.","journal-title":"Allergy"},{"key":"1050_CR7","doi-asserted-by":"publisher","first-page":"9319","DOI":"10.2147\/CMAR.S339282","volume":"13","author":"L Li","year":"2021","unstructured":"Li L, Wang L, Guan K, Liu J, Zhou D, Zhang Y, et al. Use of skin testing screening and desensitization before the first exposure of rituximab. Cancer Manag Res. 2021;13:9319\u201328.","journal-title":"Cancer Manag Res"},{"key":"1050_CR8","first-page":"e38333","volume":"15","author":"A Cottu","year":"2023","unstructured":"Cottu A, Chaara T, Car\u00e9 W, Vanquaethem H, Nielly H. Rituximab-induced serum sickness overlapping with anaphylaxis: a case report. Cureus. 2023;15:e38333.","journal-title":"Cureus"},{"key":"1050_CR9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.24953\/turkjped.2020.05.025","volume":"62","author":"MT Bayram","year":"2020","unstructured":"Bayram MT, Soylu A, Kavuk\u00e7u S. Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome. Turk J Pediatr. 2020;62:884\u20138.","journal-title":"Turk J Pediatr"},{"key":"1050_CR10","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/j.1756-185X.2011.01645.x","volume":"15","author":"A Kumar","year":"2012","unstructured":"Kumar A, Khamkar K, Gopal H. Serum sickness and severe angioedema following rituximab therapy in RA. Int J Rheum Dis. 2012;15:e6\u20137.","journal-title":"Int J Rheum Dis"},{"key":"1050_CR11","first-page":"771","volume":"57","author":"A Isoda","year":"2016","unstructured":"Isoda A, Ishikawa T, Sato N, Miyazawa Y, Matsumoto M, Sawamura M. Repeated rituximab-induced serum sickness with anaphylaxis. Rinsho Ketsueki. 2016;57:771\u20133.","journal-title":"Rinsho Ketsueki"},{"key":"1050_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000496092","volume":"179","author":"TH Kim","year":"2019","unstructured":"Kim TH, Yoon SH, Hong H, Kang HR, Cho SH, Lee SY. Duration of observation for detecting a biphasic reaction in anaphylaxis: a meta-analysis. Int Arch Allergy Immunol. 2019;179:31\u20136.","journal-title":"Int Arch Allergy Immunol"},{"key":"1050_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13223-020-00448-8","volume":"16","author":"V Polito","year":"2020","unstructured":"Polito V, Barbacki A, Isabwe G. Type I allergic reaction to rituximab upon first lifetime exposure: a case report. Allergy Asthma Clin Immunol. 2020;16:56.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-026-01050-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:09:47Z","timestamp":1790554187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-026-01050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1186\/s13223-026-01050-0","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this case report was obtained from the Ethics Committee of the Keio University School of Medicine on June 24, 2024 (Approval No. 20241053). Written informed consent for participation in this study was obtained from the patient, in accordance with relevant laws and institutional guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report and any accompanying clinical information was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}